GlassScriptPhysician profile
Michael H Annabi
NPI 1962484378
$188,178.39
in general payments reported to CMS, 2019-2025
58 companies · $20K in 2025
The $20K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $27K · 2021: $32K · 2022: $31K · 2023: $20K · 2024: $17K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Food and Beverage: $5,002 · Travel and Lodging: $2,334 · Education: $10.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50,247.94 |
| Food and Beverage | $5,002.45 |
| Travel and Lodging | $2,333.70 |
| Education | $10.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $99,190.10 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31,293.65 | 2019-2025 | Jardiance, Ofev |
| Astrazeneca Pharmaceuticals LP | $22,419.06 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Sanofi-Aventis U.S. LLC | $15,032.18 | 2019-2022 | |
| Lilly USA, LLC | $11,988.45 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $994.39 | 2019-2025 | |
| Abbott Laboratories | $881.21 | 2020-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $800.21 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $486.33 | 2020-2025 | |
| Astellas Pharma US INC | $388.92 | 2019-2024 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $384.19 | 2019-2025 | Verquvo, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $349.25 | 2019-2025 | Xifaxan, Relistor |
| Novartis Pharmaceuticals Corporation | $320.81 | 2019-2024 | |
| Amgen INC. | $262.80 | 2019-2025 | Repatha, Otezla, Otezla |
| Amarin Pharma, INC. | $261.28 | 2019-2022 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Annabi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.